Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp29719_8k.htm |
| EX-99.2 - EXHIBIT 99.2 - Shire plc | dp29719_ex9902.htm |
Exhibit 99.01
|
Press Release
|
 |
|
www.shire.com
|
Annual Information Update
April 2, 2012 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces its Annual Information Update in accordance with the requirements of Prospectus Rule 5.2. This is in relation to information that has been published or made available to the public between April 1, 2011 and March 31, 2012 (save for the final item under section 3 below which has been deemed as having been filed on March 31, 2011).
The information referred to in this Annual Information Update was correct at the time the information was published, but some information may now be out of date. The information appears by way of record and the Company is under no obligation to update it.
|
1.
|
Announcements made via a RIS
|
The documents listed below were published via a Regulatory Information Service on or around the dates indicated.
|
30-Mar-12
|
Shire Announces Top-line Results of the PREVENT2 Trial
|
|
|
22-Mar-12
|
2011 Annual Report - DTR 6.3.5 Disclosure
|
|
|
15-Mar-12
|
Shire to acquire FerroKin BioSciences, Inc.
|
|
|
15-Mar-12
|
Shire Update on US BLA Filing for REPLAGAL®
|
|
|
06-Mar-12
|
PDMR Share Dealing
|
|
|
01-Mar-12
|
Total Voting Rights
|
|
|
01-Mar-12
|
Elections for Interim Dividend
|
|
|
29-Feb-12
|
Director/PDMR Share Dealings
|
|
|
28-Feb-12
|
PDMR Share Dealing
|
|
|
27-Feb-12
|
Director Declaration
|
|
|
24-Feb-12
|
PDMR Share Dealings
|
|
|
23-Feb-12
|
PDMR Share Dealings
|
|
|
22-Feb-12
|
Director/PDMR Share Dealings
|
|
|
09-Feb-12
|
Another strong year for Shire
|
|
|
01-Feb-12
|
Total Voting Rights
|
|
|
31-Jan-12
|
Full Year 2011 results date notification - Feb 9, 2012
|
|
|
23-Jan-12
|
Holding(s) in Company
|
|
|
05-Jan-12
|
VENVANSE Marketing Application accepted for review in EU
|
|
|
03-Jan-12
|
Total Voting Rights
|
|
|
30-Dec-11
|
Director/PDMR Shareholding
|
|
|
15-Dec-11
|
Shire plc Board and Committee Changes
|
|
|
14-Dec-11
|
Director/PDMR Shareholding
|
|
|
12-Dec-11
|
Director/PDMR Shareholding
|
|
|
01-Dec-11
|
Total Voting Rights
|
|
|
01-Dec-11
|
Director/PDMR Shareholding
|
|
|
24-Nov-11
|
Block listing six monthly return
|
|
|
21-Nov-11
|
Director/PDMR Shareholding
|
|
|
07-Nov-11
|
Director/PDMR Shareholding
|
|
|
02-Nov-11
|
PDMR Share Transactions
|
|
|
01-Nov-11
|
Total Voting Rights
|
|
|
01-Nov-11
|
Director Declaration
|
|
|
28-Oct-11
|
Continued strong product sales performance in Q3
|
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
|
13-Oct-11
|
3rd Quarter Results Notification
|
|
|
03-Oct-11
|
Total Voting Rights
|
|
|
30-Sep-11
|
Director/PDMR Shareholding
|
|
|
26-Sep-11
|
Director/PDMR Shareholding
|
|
|
01-Sep-11
|
Elections for Interim Dividend
|
|
|
01-Sep-11
|
Total Voting Rights
|
|
|
25-Aug-11
|
Regulatory Approval
|
|
|
12-Aug-11
|
Purchase of Shares by Employee Benefit Trust
|
|
|
11-Aug-11
|
Half Yearly Report
|
|
|
03-Aug-11
|
Director/PDMR Shareholding
|
|
|
02-Aug-11
|
Director/PDMR Shareholding
|
|
|
01-Aug-11
|
Director/PDMR Shareholding
|
|
|
01-Aug-11
|
Total Voting Rights
|
|
|
29-Jul-11
|
Holding(s) in Company
|
|
|
28-Jul-11
|
Shire’s quarterly revenues grow by 25%
|
|
|
27-Jul-11
|
Board Changes
|
|
|
15-Jul-11
|
Second quarter 2011 results date notification
|
|
|
07-Jul-11
|
Shire files lawsuit against Watson and Roxane
|
|
|
01-Jul-11
|
Shire files lawsuit against Sandoz and Amneal
|
|
|
01-Jul-11
|
Total Voting Rights
|
|
|
28-Jun-11
|
Shire completes acquisition of Advanced BioHealing, Inc.
|
|
|
24-Jun-11
|
Purchase of Shares by Employee Benefit Trust
|
|
|
21-Jun-11
|
Director/PDMR Shareholding
|
|
|
17-Jun-11
|
Director/PDMR Shareholding
|
|
|
01-Jun-11
|
Total Voting Rights
|
|
|
25-May-11
|
Shire receives VYVANSE(R) Paragraph IV Notice Letters
|
|
|
24-May-11
|
Block listing - Six Monthly Return
|
|
|
19-May-11
|
Shire receives VYVANSE(R) Paragraph IV Notice Letter
|
|
|
18-May-11
|
Shire to acquire Advanced BioHealing
|
|
|
09-May-11
|
Director/PDMR Shareholding
|
|
|
06-May-11
|
Purchase of Shares by Employee Benefit Trust
|
|
|
04-May-11
|
Director Declaration
|
|
|
03-May-11
|
Total Voting Rights
|
|
|
28-Apr-11
|
Shire delivers a strong first quarter performance
|
|
|
26-Apr-11
|
Result of AGM
|
|
|
20-Apr-11
|
Notice of Results
|
|
|
19-Apr-11
|
Holding(s) in Company
|
|
|
06-Apr-11
|
Shire files lawsuit against Watson Pharmaceuticals
|
|
|
01-Apr-11
|
Director/PDMR Shareholding
|
|
|
01-Apr-11
|
Total Voting Rights
|
|
|
01-Apr-11
|
Annual Information Update
|
|
2.
|
Documents filed with the Securities and Exchange Commission (“SEC”)
|
The Company submitted filings to the SEC in compliance with its obligations under national laws and rules dealing with the regulation of securities, issuers of securities and securities markets by virtue of having American Depository Shares admitted to trading on the NASDAQ. Full details of these filings can be found on the SEC’s website at www.sec.gov.
2
|
3.
|
Documents filed with Companies Registry, Jersey
|
| Date of Delivery | Document | |
| 24-Feb-12 | Annual Return | |
| 17-May-11 | Special Resolutions passed on April 26, 2011 | |
| 31-Mar-11 | Annual Report and Accounts for the year ended December 31, 2010 |
|
4.
|
Documents sent to Shareholders
|
The following documents were published and sent to shareholders, and are available on the Company’s website.
| Date of Delivery | Document | |
| 22-Mar-12 | Annual Report and Accounts for the year ended December 31, 2011 | |
| 22-Mar-12 |
Notice of 2012 Annual General Meeting
|
A copy of this Annual Information Update and copies of the documents referred to in it can be obtained from the Deputy Company Secretary at the Company’s registered office.
Tony Guthrie
Deputy Company Secretary
For further information please contact:
|
Investor Relations
|
||
|
Eric Rojas
|
erojas@shire.com
|
+1 781 482 0999
|
|
Sarah Elton-Farr
|
seltonfarr@shire.com
|
+44 1256 894157
|
Notes to editors
SHIRE PLC
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com.
3